| Project/Area Number |
15K19585
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Infectious disease medicine
|
|---|
| Research Institution | Osaka University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2015-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Keywords | カルバペネム耐性腸内細菌科細菌 / セファマイシン / セフメタゾール / メロペネム / 併用療法 / NDM / IMP / KPC / 薬剤耐性菌 / リバイバル / ラタモキセフ / ホスホマイシン / カルバペネム |
|---|
| Outline of Final Research Achievements |
Antimicrobial resistance, especially carbapenemase-producing Enterobacteriaceae (CPE), is an ongoing problem that globally undermines medical settings. Considering the high cost of developing new classes of antibiotics, “revival use” of existing antimicrobial agents provides another option to combat the highly resistant microorganisms. In this study, we assessed in vitro efficacy of combination therapy with meropenem and cefmetazole against various carbapenemase-producing Enterobacteriaceae. We applied standard checkerboard and time-kill assays, and revealed a therapeutic possibility of this new combination therapy. Further research on the pharmacokinetic and pharmacodynamics utility, as well as optimal therapeutic regimen and clinical outcomes, should be warranted.
|
